Insmed Incorporated (INSM)

Nasdaq · Bridgewater, New Jersey, USA · Founded 1988 · CEO Will Lewis

Valuation summary

$114.11 fair value versus $144.46 in the market, a difference of -21.0%. Rated Reduce.

Fair value per share$114.11
Current share price$144.46
Upside / downside-21.0%
Bear case$76.68
Bull case$164.29
Discount rate (WACC)10.4%
Terminal growth3.00%
Market capitalisation$32B
EV / Sales21.2x

About Insmed Incorporated

Will Lewis has been chief executive since 2012. Insmed develops medicines for serious lung diseases. Its first product, Arikayce, treats a hard-to-cure lung infection. In August 2025 US regulators approved Brinsupri, the first medicine for bronchiectasis, a chronic condition in which damaged airways cause repeated infections and which affects several hundred thousand Americans. The launch has been one of the fastest in recent years, and a third medicine for high blood pressure in the lungs is in late-stage trials.

Investment case

  • Brinsupri is the only approved treatment for a common, long-neglected disease.
  • The same drug is being tested in other inflammatory conditions.
  • A late-stage pipeline beyond its two products.

Key risks

  • Still loss-making while it funds a large launch.
  • Other companies are developing drugs of the same type.
  • Recent trial setbacks in new uses show the risk in the pipeline.

Revenue by segment

Brinsupri60%
Arikayce40%

Five-year forecast

RevenueFree cash flow
Year 1$2.4B$-0.5B
Year 2$3.8B$-0.3B
Year 3$5.3B$0.2B
Year 4$6.8B$0.9B
Year 5$8.1B$2.0B

What the street says

Seen as one of the most important new drug launches in biotech.

Comparable companies: MRNA · TEM · ALNY · NTRA · HUM · CNC · CAH · DXCM

Open the interactive model, price chart and sensitivity grid →